BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29027153)

  • 1. Conflicting Data on the Incidence of Leukopenia and Neutropenia After Heated Intraperitoneal Chemotherapy with Mitomycin C.
    Feferman Y; Bhagwandin S; Kim J; Aycart SN; Feingold D; Labow DM; Sarpel U
    Ann Surg Oncol; 2017 Dec; 24(13):3831-3836. PubMed ID: 29027153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Hakeam HA; Arab A; Azzam A; Alyahya Z; Eldali AM; Amin T
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):697-704. PubMed ID: 29429054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy.
    Kemmel V; Mercoli HA; Meyer N; Brumaru D; Romain B; Lessinger JM; Brigand C
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S873-9. PubMed ID: 26100819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
    Hompes D; D'Hoore A; Wolthuis A; Fieuws S; Mirck B; Bruin S; Verwaal V
    J Surg Oncol; 2014 May; 109(6):527-32. PubMed ID: 24375059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C.
    Lambert LA; Armstrong TS; Lee JJ; Liu S; Katz MH; Eng C; Wolff RA; Tortorice ML; Tansey P; Gonzalez-Moreno S; Lambert DH; Mansfield PF
    Ann Surg Oncol; 2009 Aug; 16(8):2181-7. PubMed ID: 19475451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
    Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
    J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial Properties of Perfusate Fluid After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CS-HIPEC) with Mitomycin C.
    Lange KN; McKay D; Gentry BG; Franko J
    Ann Surg Oncol; 2017 Dec; 24(13):3837-3841. PubMed ID: 29019106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
    Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
    J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC.
    Abel ML; Kokosis G; Blazer DG
    World J Surg Oncol; 2017 Feb; 15(1):49. PubMed ID: 28219391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
    van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
    Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
    Bhagwandin SB; Naffouje S; Salti G
    J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematological toxicities associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Wong EYT; Tan GHC; Kumar M; Teo MCC
    Asia Pac J Clin Oncol; 2020 Apr; 16(2):e38-e46. PubMed ID: 31693307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O
    Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.
    Downs-Canner S; Ding Y; Magge DR; Jones H; Ramalingam L; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2015 May; 22(5):1651-7. PubMed ID: 25348781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
    Martin AS; Abbott DE; Hanseman D; Sussman JE; Kenkel A; Greiwe P; Saeed N; Ahmad SH; Sussman JJ; Ahmad SA
    Ann Surg Oncol; 2016 Jun; 23(6):1941-7. PubMed ID: 26842489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.
    Leung V; Huo YR; Liauw W; Morris DL
    Eur J Surg Oncol; 2017 Jan; 43(1):144-149. PubMed ID: 27780675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis.
    Lee SJ; Jeon Y; Lee HW; Kang J; Baik SH; Park EJ
    Ann Surg Oncol; 2022 Mar; 29(3):2077-2086. PubMed ID: 34665362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.